All News

On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the June 2023 issue of The American Journal of Managed Care® about how employers and their employees are utilizing direct-to-consumer telehealth to reduce the cost of care.

The infrastructure also provides a blueprint for similar initiatives in other rare diseases.

A new review outlines strategies that may help reduce the risk of severe cytokine release syndrome (CRS) for patients treated with immunotherapy.

The Act4Biosimilars Action Plan seeks to increase biosimilar adoption by at least 30 percentage points in 30-plus countries by 2030.

A new model produces information that can lead to individual providers identifying women who may need more targeted and more frequent HIV testing or be good candidates for preexposure prophylaxis.

The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited.

Since 1930, there have been fewer than 1000 cases of the disease reported around the world.

Matthew Mansh, MD, FAAD, discusses inequities faced by transgender and gender-diverse patient populations.

The advent of gene therapies, which can target specific variants, means pinpointing the genetic roots of each patient’s disease has taken on new importance, researchers said.

The model has potential to assist integrated delivery network health care providers through early identification of patients with pulmonary arterial hypertension (PAH), a rare but fast-progressing condition.

New findings show that VX-880, a stem cell-derived islet cell therapy, can restore endogenous insulin secretion and improve glycemic control in people living with type 1 diabetes (T1D).

The cross-sectional study of 260 people with epilepsy collected data between October and December 2020, months following the onset of the pandemic in the United States.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention,"Ann Cameron, PhD, says.

A recent study found that depressive symptoms improved among patients with severe asthma who responded to monoclonal antibody (mAb) therapy, but baseline depression symptoms were associated with lower therapy response rates.

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.

E-cigarette sales dropped in 2022 following a spike; President Joe Biden will sign an executive order designed to guard and expand contraception access; Ochsner Health and MD Anderson Cancer Center are partnering to serve patients in Louisiana with cancer.

Researchers discovered that exercise helps to alleviate various symptoms for patients with chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, interstitial lung disease, and lung cancer.

A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.

Idiopathic hypersomnia treatment should be determined based on factors like symptom profile, age, comorbidities, and additional medications, says review.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.

Multiple risk factors for uncontrolled asthma include racial and ethnic barriers, as well as health insurance status, according to one study.

Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance.

New estimates predict that type 2 diabetes prevalence will more than double in the next 30 years, from 529 million people in 2021 to at least 1.3 billion in 2050.

Shifts in clinical treatment patterns could prompt investigators to revisit the cost-effectiveness question.

Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.

The US federal government is finally updating its standards for reporting data on race and ethnicity – and it’s an urgently needed chance to enable a national overview of crucial data on health inequities

A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.